![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 35, 24694-24702, August 27, 1999
From the The nitric-oxide synthase (NOS) catalyzes the
oxidation of L-arginine to L-citrulline
and NO through consumption of oxygen bound to the heme. Because NO is
produced close to the heme and may bind to it, its subsequent role in a
regulatory mechanism should be scrutinized. We therefore examined the
kinetics of NO rebinding after photodissociation in the heme pocket of
human endothelial NOS by means of time-resolved absorption
spectroscopy. We show that geminate recombination of NO indeed occurs
and that this process is strongly modulated by L-Arg. This
NO rebinding occurs in a multiphasic fashion and spans over 3 orders of
magnitude. In both ferric and ferrous states of the heme, a fast
nonexponential picosecond geminate rebinding first takes place followed
by a slower nanosecond phase. The rates of both phases decreased,
whereas their relative amplitudes are changed by the presence of
L-Arg; the overall effect is a slow down of NO rebinding.
For the isolated oxygenase domain, the picosecond rate is unchanged,
but the relative amplitude of the nanosecond binding decreased. We
assigned the nanosecond kinetic component to the rebinding of NO that
is still located in the protein core but not in the heme pocket. The
implications for a mechanism of regulation involving NO binding are discussed.
The enzyme nitric-oxide synthase
(NOS)1 has been identified in
mammals as three different isoforms, which have been cloned and
expressed (1, 2). Although it is inducible in macrophages, the two
other forms are constitutive in neurons and in endothelial cells. Its
presence was also recently demonstrated in liver mitochondria (3). NOS
isoforms catalyze the formation of highly diffusible NO and are
involved in several physiopathologic events (4-6). For instance,
hypertension is associated with a deficiency of NO production, whereas
excessive amounts of NO lead to hypotension. For blood pressure
regulation, NO released from eNOS acts as an intermediate messenger in
endothelial cells, targeting the enzyme guanylyl cyclase (7), which is
activated and catalyzes the production of cGMP from GTP.
NOS catalyzes the oxidation of L-Arg to
L-citrulline through O2 consumption to produce
NO in presence of NADPH, tetrahydrobiopterin, FAD, FMN, and
Ca2+-calmodulin (8-10). The NOS structure is organized in
two distinct domains, a reductase domain that binds FMN and FAD and an
oxygenase domain that harbors the heme (iron-protoporphyrin IX) for
O2 ligation. The triggering role of calmodulin has been
explained by a switch mechanism between the reductase and oxygenase
domains mediating electron transfer from, respectively, NADPH to FAD,
to FMN, and then to the heme (11, 12). In the resting state, iron is
ferric and five-coordinated with an axial ligand of Cys (13). The
oxygenase domain can be expressed separately in an active form that
binds cofactors (14). The formation of NO occurs in two steps and requires two molecular O2 and 1.5 equivalent of NADPH (8,
15). N-Hydroxy-L-arginine is generated in the
first stage of reaction and is subsequently further oxidized to the
final products L-citrulline and NO. It has been shown by
isotopic substitution that the nitrogen atom of NO comes from the NOH
group of the intermediate N-hydroxy-L-arginine (8). The proposed reaction mechanisms involve the formation of a
transient Fe2+ species before O2 ligation and a
Fe3+ one in the last step when L-citrulline and
NO are formed (15, 16).
Several isoform-selective inhibitors of NOS are analogs of
L-Arg with a modified guanidinium group such as
propyl-L-Arg (17) or aminoguanidine (18), which may
interfere with other L-Arg-utilizing enzymes. Because NOS
possesses several cofactors and binds three substrates for NO
synthesis, it may be regulated in different ways. This regulation is
essential because NO is a very reactive species that cannot be stored.
For therapeuthics purposes, a detailed study of the regulation of the
isoforms is of prime importance because inhibiting or enhancing the
activity of one isoform without perturbing the others can be
beneficial. A possible mechanism of regulation is through
self-inhibition; although the NOH group from which NO is derived may
not directly interact with the heme during oxidation of
N-hydroxy-L-arginine, NO is released in close vicinity of the heme, and its subsequent binding to the heme must therefore be considered. Indeed, a 2-fold increase of the catalytic activity of the inducible murine NOS has been reported when
oxy-hemoglobin, a NO scavenger, is present during the reaction cycle
(19), but this effect was not observed for the constitutive murine
neuronal NOS (20). It was shown that NO decreased nNOS activity (21) and that a ferric-nitrosyl complex formed during catalytic activity in
the case of inducible NOS (19) as well as a ferrous-nitrosyl complex
formed independently of exogenous NO concentration during activity of
nNOS (20). Such observations are not yet reported for eNOS.
Furthermore, the presence of NO scavengers such as oxyhemoglobin or
superoxide did not increase the activity of nNOS, nor did they preclude
the formation of the nitrosyl complex. Because the use of NO scavengers
allows investigation only of diffusion controlled mechanisms of
inhibition, these observations suggest that two phases occur in
self-inhibition of nNOS by NO, one of which involves a fast step in
which NO binds to the heme right after synthesis, before diffusing out
of the heme pocket. We addressed this issue at a molecular dynamics
level by using time-resolved absorption spectroscopy, which powerfully
relates structural properties and dynamical behavior. This is a
particularly well suited technique because it allows simulation, by
means of photodissociation, of the release of newly synthesized NO in
the heme pocket. To follow the behavior of released NO and the
parameters influencing the heme-NO interaction, we analyzed the
rebinding of NO to eNOS after photolysis in both ferric and ferrous
states of the heme and in the presence or absence of the substrate
L-arginine.
L-Citrulline was from Alexis Biochemicals (San
Diego, CA). L-[2,3,4,5-3H]Arginine was
obtained from Amersham Pharmacia Biotech (specific activity, 77 Ci/mmol). (6R)-5,6,7,8-Tetrahydro-L-biopterin
(BH4) was obtained from Research Biochemical International.
Gas was purchased from Alphagaz. All other chemicals used for
purifications or spectroscopy were purchased from Sigma.
Expression and Purification of eNOS and Oxygenase Domain of
eNOS--
Recombinant human eNOS and oxygenase domain of eNOS were
prepared using the baculovirus expression system. The
BH4-depleted eNOS was expressed in Escherichia
coli. Expression and purification of recombinant proteins were
essentially the same as described previously (14, 22). The purified
enzyme preparations were stored at liquid nitrogen in buffer containing
50 mM Tris-HCl, pH 7.5, 10% glycerol, 0.15 M NaCl.
Assay of Enzyme Activity--
NOS activity was assayed by
measuring conversion of L-[3H]arginine to
L-[3H]citrulline (13). The reaction mixture
containing 50 mM Tris-HCl, pH 7.5, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM dithiothreitol, 0.2 µM calmodulin, 1 mM CaCl2, 100 µM Biopterin Determination--
The BH4 content of
purified eNOS and its oxygenase domain were measured as described
previously (13) and quantitated from a standard curve of authentic
BH4. The BH4 stoichiometry was determined to be
0.5-0.6 mol of BH4/mol of protein in eNOS and 0.3 mol of BH4/mol of oxygenase domain, respectively.
Preparation of Samples for Spectroscopy--
After thawing, 100 µl of eNOS (60 µM) were put in a 1-mm optical path
quartz cell sealed with a rubber stopper and immediately degassed with
at least five cycles of vacuum and purging with argon (99.9999%). When
indicated, 8 µl of 60 mM L-Arg were added using a gas-tight syringe (Hamilton) previously rinsed with argon (final concentration, 5 mM; KD of
L-Arg for eNOS is 2 µM). This addition of
solution balanced the change of volume because of vacuum evaporation of
water. For preparing NO-liganded ferric eNOS, pure NO (99.99%) was
directly applied in the cell through the gas train at a total pressure
of 1.3 bar (about 2 mM of NO in the aqueous phase). A
second stopper was placed on the cell. Equilibrium spectra were
recorded at each step of the process.
For reduction of L-Arg bound eNOS, 5 µl of a 20 mM Time-resolved Spectroscopy--
Time-resolved spectroscopy was
performed with the pump-probe laser system previously described (26).
Photodissociation of NO was achieved with an excitation wavelength in
the The equilibrium spectra of unliganded and NO-liganded species of
eNOS are displayed together with the difference spectra in Fig.
1. When NOS is unliganded, the Soret
maximum is located at 398 nm for the oxidized form and at 412 nm for
the NADPH-reduced form. Upon ligation of NO, the maximum is shifted to
441 and 434 nm for ferric and ferrous eNOS, respectively. The
difference spectrum (Fig. 1A) for ferric eNOS discloses a
characteristic minimum at 443 nm (shifted by 2 nm with respect to the
maximum of NO-liganded eNOS Soret band). The Soret shift induced by NO
binding is the opposite of that observed for histidine-coordinated iron
proteins such as myoglobin or hemoglobin. When L-Arg is
added to the ferric form (Fig. 1B), there is a slight shift
from 398 to 395 nm, providing evidence for a modification of the heme
electronic state.
The transient spectra (raw data) are shown in Fig.
2. Each of them corresponds to the
calculated difference between a spectrum at the indicated time and the
spectrum before photodissociation. For ferric eNOS alone, the transient
spectra at all time points (Fig. 2, top panel) showed a
minimum at the same position as the equilibrium spectrum (443 nm)
corresponding to the photodissociation of NO. From 8 ps to 4 ns, the
transient spectra have the same shape and exhibit a decreasing
intensity because of rebinding of NO. The 2-ps spectrum has an
isosbestic point around 423 nm slightly shifted by about 2 nm with
respect to that of the longer time spectra. This is the only feature
showing the presence of an intermediate before the rebinding of NO to
the ferric ground state species. When L-Arg is bound to
ferric eNOS, the transient spectrum at 2 ps discloses absorption maxima
centered at 415 and 465 nm. The isosbestic point moves from 428 nm at 2 ps to 423 nm at 4 ns, and the second isosbestic point, which was
constant at 467 nm in the absence of L-Arg, is greatly
displaced from 455 nm at 2 ps to 465 nm at 4 ns in the presence of
L-Arg. These features are not observed in the case of
ferric eNOS alone, whereas they are more pronounced in the 2-ps
transient difference spectrum of L-Arg-bound and
NADPH-reduced eNOS, indicating that the photodissociated excited state
heme is different when the substrate L-Arg is bound. For
ferrous eNOS, the amplitude of the transient difference spectra at 4 ns
remains high, indicating a long-lived component. In all three
conditions, the 8-ps to 4-ns spectra correspond to rebinding without
contribution from transient excited species.
Geminate Recombination of Nitric Oxide to Endothelial
Nitric-oxide Synthase and Mechanistic Implications*
§,
,
,
,
INSERM U451, Ecole Nationale
Supérieure des Techniques Avancées Centre de l'Yvette,
Chemin de la Hunière, 91761 Palaiseau Cedex, France and the
¶ Division of Hematology, Internal Medicine, University of Texas
Medical School at Houston, Houston, Texas 77030
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-NADPH, 10 µM BH4, 100 µM L-arginine, and 1 µCi of
L-[3H]arginine was incubated with enzyme at
37 °C for 3 min.
-NADPH solution, degassed under vacuum and argon,
were added to the sample (final concentration, 1 mM;
[NADPH]/[heme] = ~17). No calmodulin was added. To get
NO-liganded ferrous eNOS, 0.5% NO (diluted in nitrogen; total
pressure, 1.3 bar) was introduced in the cell yielding a NO
concentration of 10 µM in the aqueous phase. This avoids
reoxidation of the heme because of high concentration of NO (23). The
evolution of the Soret band was then monitored. In early experiments we
tried sodium dithionite for reducing eNOS, but this appeared not
suitable for time-resolved spectroscopy because we observed a
photoinduced depletion of NO because of a reaction between NO and
sodium dithionite. The ferrous nitrosyl complex in the absence of
L-arginine was too labile (24, 25) for time-resolved
measurements and was not exploited further. Horse heart myoglobin (80 µM) was prepared from lyophilized powder (Sigma)
dissolved in 50 mM Tris, pH 7.5, and reduced with sodium dithionite.
band, either at 563 or at 580 nm with a pulse width of 40 fs.
The transient absorption after a variable delay was probed with a wide
spectrum pulse from a continuum, whose group velocity dispersion was
minimized at 413 nm by means of prisms. The same sample quartz cell
(1-mm optical path length) was used for recording equilibrium spectra and for kinetic measurements; it was continuously moved perpendicularly to the laser beams during the recording. The absorbance of samples was
in the range 0.5-0.8 at Soret maximum for 1 mm, and the temperature was 18 °C. Time windows of 20 and 300 ps were scanned. 20-60 scans were recorded and averaged. Nanosecond kinetics were recorded in
separate measurements by means of the same set up as picosecond kinetics, to maintain the same duration and spectrum of the pulses, while extending the total length of the delay line. In this case the
dwell time was 6 s at each point, and 8-12 scans were averaged. Analysis of the data was performed by singular value decomposition (SVD) of the time-wavelength matrix (27), and the kinetics associated with the SVD component having the highest singular value were fit with
a minimum number of exponential components. It was not necessary to
take into account the pulse shape because it is 1 order of magnitude
shorter than time increment between two transient spectra. An
additional analysis of the kinetics was performed using the maximum
entropy method (MEM) to obtain the distribution of rates (28, 29).
Recording of NO-liganded reduced myoglobin kinetics was performed under
the same conditions.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (26K):
[in a new window]
Fig. 1.
Absolute and difference equilibrium spectra
of eNOS whose transient spectra were recorded. Before subtraction,
the absolute spectra were normalized at 280 nm. Optical path length is
1 mm. The solid line represents unliganded species; the
dotted line represents liganded species; and the
dashed line represents the difference spectrum.
A, ferric NOS, difference is unliganded minus NO-liganded.
B, ferric NOS, difference spectrum is
L-Arg-bound eNOS minus unbound eNOS. C,
NADPH-reduced NOS, difference spectrum is unliganded minus NO-liganded.
The rising side at 390 nm not seen in the transient spectrum (Fig. 2)
is due to the change in redox state of NADPH and the absorption after
adding NO. D, L-Arg-bound ferric eNOS,
difference spectrum is unliganded minus NO-liganded.

View larger version (22K):
[in a new window]
Fig. 2.
Transient spectra (raw data) for the NO
rebinding for the three indicated species at four selected times after
photodissociation of NO (spectra at 90 different time delays were
recorded for each species).
To disentangle the contributions from the different transient species
and their associated kinetics, we performed SVD analysis of the raw
data. The 300-ps and the 4-ns time windows were recorded sequentially,
and SVD analysis were performed separately. This resulted in two main
spectral components displayed in Fig. 3
and compared with the equilibrium unliganded minus NO-liganded
difference. Although a SVD spectral feature does not necessarily
correspond to a particular chemical species, it does in this present
case; for the three species, the spectral component having the highest singular value (SVD1) matches the deligandation difference equilibrium spectrum. The associated kinetics displayed in Fig.
4 thus represent the evolution of
unliganded ground state eNOS and the subsequent rebinding of NO. In all
cases this SVD component had the same spectrum in both time windows,
which were therefore fit simultaneously to obtain kinetic parameters
describing the overall spectral evolution. According to the
physiological function of eNOS, the release of a certain amount of NO
is expected to occur, and we thus needed a constant term for fitting
the kinetics for the three conditions. The minimal model that we used
for describing the kinetics of unliganded ground state species and NO
rebinding has up to three exponential decay components and a constant
term. The decay components and constant term are associated with the
same transient species, which is similar to the liganded-unliganded
difference equilibrium spectrum (Fig. 3) having identical positions for
minimum and isosbestic points. Therefore, these kinetic components
represent different phases of NO rebinding for the three species. The
parameters of the fits are listed in Table
I.
|
|
|
In all cases a 5-ps rise was also present in the kinetics (not shown) associated with the SVD2 spectral component (Fig. 3) and is assigned to the formation of unliganded ground state species from the excited state. This component produced the change of isosbestic point near 423 nm seen in the raw spectra (Fig. 2) at 2 ps. The early time photophysics of eNOS heme will be discussed elsewhere.
Ferric NOS--
The fit of kinetics associated with the SVD1
spectrum revealed three decay components and a constant (Fig. 4 and
Table I) whose associated spectra are shown in Fig. 3A. The
fast decay (
1 = 15 ps) and the intermediate one
(
2 = 200 ps) are two phases of the recombination with NO
still located in the heme pocket, as seen for other hemoproteins, and
represent together 37% of the total rebinding. The long time component
(
3 = 2 ns) represents a rebinding phase of NO not
necessarily located in the heme pocket. The constant term of 10%
relative amplitude may be due either to a much longer time rebinding or
to NO diffusing into the solution. About 34% of the photodissociated
NO has rebound after 300 ps and 85% after 4 ns (Fig. 4).
L-Arg-bound Ferric NOS--
When L-Arg is
bound, the fit of kinetics also resulted in three decay terms. The SVD2
component has a spectrum quite different from that obtained in the
absence of L-Arg (Fig. 3B), especially around
460 nm, and is the origin of the conspicuous shift of isosbestic point
from 455 to 465 nm in the raw spectrum (Fig. 2B). Compared with free eNOS, the presence of L-Arg increased the time
constant of the fast NO-rebinding to 53 ps (Table I) and its relative amplitude 4-fold. Simultaneously, the amplitude A2 of the
intermediate rebinding phase was decreased 2-fold, whereas the long
time constant increased dramatically to
3 = 17 ns (it
may also contain a constant term). Along with the increase of
A1, L-Arg binding resulted in the
crossing of the normalized kinetics. The change of
1 and
2 is seen in the first time window (Fig. 4), whereas
that of
3 is evident in the second time window. About
36% of NO rebound after 300 ps and 50% after 4 ns. Thus the overall
effect of L-Arg is a greatly reduced rate of recombination,
whereas the phases are differently affected.
Importantly, there is no spectral SVD component (Fig. 3B) matching the difference spectrum of L-Arg deligation from eNOS (Fig. 1B); therefore we readily concluded that photodissociation of L-Arg did not occur and that rebinding of NO occurred when L-Arg remained bound. This also holds true for ferrous NOS.
NADPH-reduced NOS-- For preparing ferrous eNOS we did not add calmodulin prior to adding NADPH. After reduction with NADPH the equilibrium spectrum discloses a Soret located at 412 nm, characteristic of unliganded reduced eNOS, similar to that obtained with sodium dithionite, which can reduce heme without calmodulin. Subsequent addition of NO shifted the Soret maximum of the NADPH-treated sample to 434 nm, again identical to that of eNOS reduced with sodium dithionite, and is clearly not the position for the NO complex of ferric eNOS (441 nm). A residual amount of calmodulin carried along the eNOS purification appears to sustain electron transfer from FMN to the heme (30). Because the reduction using NADPH may not lead to a full reduction of NOS (19), we expected that this sample contained an amount of unliganded oxidized heme, the absorption band of which is hidden by that of NADPH. The affinity for NO is higher for ferrous than for ferric eNOS (KD is 65 µM and ~nM for ferric and ferrous form, respectively2), and we used a NO concentration of 0.5% in the gas phase; this gave an aqueous NO concentration too low for binding to ferric eNOS. Thus the fraction of the remaining ferric eNOS that is NO-liganded is negligible, and the NO rebinding kinetics is only due to ferrous eNOS. This is not true for the kinetics of excited states (SVD2 spectral component), which may be a mixture of contributions from both oxidized and reduced L-Arg-bound species.
As seen for the ferric eNOS, the NO rebinding proceeds with three
exponential decays. The time constant of fast geminate rebinding decreased slightly for ferrous eNOS (
1 = 36 ps) compared
with ferric eNOS (
1 = 53 ps). Interestingly, the
relative amplitude of the picosecond components, associated with NO
rebinding still located in heme pocket, decreased, whereas that of the
long one increased (
3 = 18 ns, A3 = 0.63). The multiple phases have time constants quite similar to those
of L-Arg-bound ferric eNOS (Table I), but the general trend
is a slightly slower rebinding than for ferric eNOS.
Because the combination of exponential values obtained from the fits
are one of the most probable set, but not the unique solution, we
analyzed the kinetics by another method: the MEM (28), which enables a
better estimate of the uncertainty of the kinetic components. We
obtained a rate distribution a(k) (Fig. 4B) for the three NO-liganded species. For the ferric NOS,
three peaks are separated from each other by 1 order of magnitude
(5 × 10
2, 5 × 10
3, and 5 × 10
4 ps
1) corresponding to the
exponential lifetimes for ferric eNOS in Table I, and the amplitude
a(k) tappers off at rates slower than 10
4 ps
1, indicating the completeness of
rebinding in this case. The relative amplitudes
a(k) of the rates match those of the components
Ai. For ferric eNOS with L-Arg, there is
only one peak centered at 100 ps
1, the broadness of which
reflects the uncertainty in determining the rates; indeed, if two rates
lie too close to each other, depending on signal/noise ratio, MEM
analysis may not separate them as distinct rates (31). By
multiexponential fitting, we obtained 53- and 300-ps lifetimes, whose
ratio (5.7) represents the resolution limit of MEM with the
signal/noise ratio of our data. Importantly, the distribution amplitude
rises at low rates showing that rebinding is incomplete and that the
slowest rate (<10
4 ps
1) may include a
constant term. For the third species, ferrous eNOS with
L-Arg, two peaks are located at 2.5 × 10
3 and 2 × 10
2 ps
1
matching the picosecond exponential rebinding components and disclosing
an inverted ratio of amplitudes when compared with ferric eNOS. As in
the case of ferric eNOS with L-Arg, the amplitude rises at
low rates, revealing the incompleteness of rebinding. Fig.
4C shows the comparison of rate distribution for ferric eNOS and for myoglobin and revealed the overall faster rebinding to this
latter hemoprotein, which was dominated by a bigger amplitude of the
faster rate, whereas the slowest phase dominates that for the ferric
eNOS.
BH4-depleted Ferric eNOS--
To estimate whether the
BH4 content has an effect on geminate NO rebinding, we
compared the kinetics of BH4-depleted eNOS expressed in
E. coli with that of eNOS containing 0.5 mol of
BH4/mol of protein, expressed with the baculovirus system
(Fig. 5A). The kinetics are
very similar, even on the nanosecond time scale. We therefore conclude
that, in contrast to L-Arg, BH4 has no major effect on NO rebinding. This result is consistent with recent stopped
flow measurements, which did not show an obvious effect of
BH4 on NO binding2 and with the x-ray
diffraction results (39), clearly indicating that the presence or
absence of BH4 does not change the structure in the
vicinity of the heme or the O2 binding pocket of eNOS.
|
Ferric Oxygenase Domain--
The rebinding of NO to the isolated
oxygenase domain in the ferric state also proceeds through
multi-exponential kinetics and is compared (Fig. 5B) with
that of entire eNOS. The rates of kinetic components are similar for
both species, but the relative amplitudes of the picosecond geminate
rebinding (A1 = 0.25) decreased with respect to
that of ferric eNOS possessing the reductase domain (A3 = 0.40) with subsequent increase of the
nanosecond rebinding. The MEM analysis of the rate distribution (Fig.
5C) provides a striking contrast between the entire eNOS and
its isolated oxygenase domain. The higher rate (~0.03
ps
1) is clearly the same for both species; as for the
slower rate, it appears as a large peak for entire eNOS, in agreement
with the higher amplitude of the 300 ps component with respect to the short one (Table I) and is followed by a nonzero amplitude. For the
oxygenase domain this peak displays a much smaller relative amplitude
and is replaced by an increased plateau matching the slow and constant
terms in the time representation.
| |
DISCUSSION |
|---|
|
|
|---|
Nitrosyl complexes have been detected during the catalytic activity of the enzyme; there is a ferrous one in neuronal NOS (20), whereas for inducible NOS the ferric nitrosyl complex was observed (19). These complexes may be relevant to regulation of the enzyme activity. To probe the dynamics of NO released from N-hydroxy-L-arginine intermediate in eNOS heme pocket, we performed time-resolved absorption measurements. We emphasize that the photodissociation of NO previously liganded to the heme mimicks the release of NO newly formed in the heme pocket.
After photodissociation, rebinding of NO occurs in a multiphasic
fashion. For all the NOS species probed here, the geminate rebinding
decomposes in two phases, a nonmonoexponential picosecond binding
(15-53 ps and 0.2-0.4 ns) and a longer one (
2 ns). Similarly to
wild type and mutants NO-liganded myoglobin, the picosecond phase is
due to rebinding of NO that did not escape the heme pocket after
photodissociation (32-35). This nonexponential character of the
picosecond geminate recombination has been interpreted as a
distribution of substates of the protein (36) and/or as a relaxation
process of the heme pocket following photodissociation and developing
simultaneously to the rebinding (32). Whatever model is considered, the
structure of the distal side of heme pocket as well as the structural
fluctuations influence the picosecond rebinding (33, 37). Because of
the difference in nature of the proximal side chain covalently bound to
the iron (Cys for eNOS; His for myoglobin) there should be a
differential trans-effect between both proteins. However, this effect
influences off rates, and our experiment probes
on rates (more precisely a step of the process determining
the on rate). The energy of photodissociation was in excess
so that any difference in binding energy because of different proximal
ligands does not affect the process. The overall rebinding of NO to
eNOS is much slower than that measured for myoglobin (Fig. 4), in
agreement with a lower affinity that is expected for an enzyme
functionally releasing NO. The existence of a structure much more
complex than that of myoglobin may account for the additional
nanosecond phase of rebinding in eNOS and gives grounds to the
comparative studies between the whole eNOS and its isolated oxygenase domain.
The Isolated Oxygenase Domain-- In the isolated oxygenase domain, the rates of both phases of the geminate recombination of NO are similar to that of entire eNOS. The striking contrast of MEM rate distribution (Fig. 5C) shows that the higher rate, corresponding to the rebinding of NO still located in the heme pocket, is the same whether the oxygenase domain is isolated or not. Geminate recombination rates are very sensitive to small structural changes; a single mutation in the heme pocket such as V68A in myoglobin changed the rate of NO rebinding (33). Thus, the similarity of picosecond rates for eNOS and the isolated oxygenase domain shows that the surroundings of the heme pocket structure in the latter are unperturbed, consistent with its unchanged catalytic properties (14). However, the relative amplitudes of the picosecond and nanosecond phases changed. As seen in the MEM analysis, the slower rate distribution has a markedly decreased amplitude correlated with a simultaneous increase of a plateau because of the constant term. This is consistent with a smaller proportion of NO rebinding from protein core to the heme and more NO escaping to the solvent in the absence of the reductase domain. As shown by the crystal structure (38, 39), the heme is located on a side of the oxygenase domain and therefore possibly influenced by the reductase domain. Thus the isolation of this domain does not alter the structure of heme pocket nor the gating from it but instead changes the gating of a possible channel leading to it from the solution. We assign the nanosecond phase to the rebinding of NO having left the heme pocket but still within the protein molecule. This may be due to a cavity such as that revealed in the crystal structure of the heme domain dimer (38, 39), which may be a channel for access of NO, L-Arg, and O2.
Effects of L-Arg on NO Rebinding-- Neither BH4 nor L-Arg is required for dimerization of eNOS (39-42), and we ruled out the possibility that the effects observed in this study upon addition of L-Arg are due to dimerization. Two conspicuous effects are induced upon binding of L-Arg to its site: a change of the transient spectra at early time after photodissociation of NO from ferric heme and a change of the relative amplitudes of the three kinetic components. Dual effects of L-Arg are revealed by multiexponential fitting and by MEM analysis (Fig. 4). Despite a slight increase of the picosecond rate, the overall effect is a dramatically slowed recombination. For the picosecond phase, the presence of L-Arg in its binding site results in an increase of the fast component relatively to the slower ones. Clearly, the binding of L-Arg changes the heme environment and the energy barrier for rebinding.
The conformation of the heme pocket in the distal side influences the rate distribution of the picosecond rebinding. This was shown for NO geminate recombination in myoglobin by means of distal side mutations such as V68X (33, 37). Similarly, a different behavior of the picosecond and the nanosecond components was observed (34) when comparing mutants differing by the size of a residue (Leu29) located in the distal side of the heme pocket. These results suggest that this side chain is located on the way out of the protein from the iron and acts as a barrier both for ligand escape and for rebinding from the exterior of the heme pocket. Furthermore, an inverse correlation was observed between the overall dissociation rate (koff) and the picosecond rate of the geminate rebinding, suggesting that the same barrier influences both rates. As indicated by simulations for myoglobin (34, 43), variations of the rate of recombination are correlated with the size of a mutated residue (L29X) in the distal side that decreases the volume available for the ligand and consequently constrains the diffusion of NO in the pocket. Steric parameters thus affect the picosecond rebinding. L-Arg is H-bound to a Glu side chain (Glu361 for human eNOS) (39, 44) in such a way that its guanidinium part is in close vicinity of O2 liganded to the ferrous heme. The presence of L-Arg could therefore sterically hinder NO rebinding, slowing down the rate of NO exchange from and/or to the heme. This observation corroborates with recent stopped flow data of NO binding to the ferric eNOS. L-Arginine binding caused a 2-3 order decrease in the observed rates of NO binding.2
In addition to this direct steric effect, there may be structural effects. Indeed, mutations on the myoglobin molecular surface have been shown to influence picosecond rebinding (33), suggesting subtle changes of the heme pocket structure or of protein relaxation, and conformational changes after photodissociation have been revealed by time-resolved absorption (45) and by computation (46). Furthermore, the access of ligands to the heme iron of myoglobin is affected by structural fluctuations that depend strongly on the structural pattern (35). As revealed by EPR experiments, the binding of L-Arg to its site changes the spin-state of the heme in both eNOS (47) and nNOS (48, 49) and induces a shift of the Soret band in the unliganded ferric NOS spectrum (Fig. 1B and Refs. 22 and 50) without direct interaction with the heme iron. These equilibrium measurements underline a structural change in the heme pocket, and the dynamics effects shown by our measurements may be related to such a structural perturbation induced by the substrate, because all three phases of NO rebinding in eNOS are changed upon L-Arg binding, and the excited state has a different spectrum in the presence of L-Arg.
It is likely that L-Arg and NO access their respective sites through the same channel. Indeed, the structure of eNOS suggests that dimerization results in the formation of a channel leading to the heme pocket (39). Because the baculovirus-expressed eNOS is mostly in dimeric form, the presence of a channel leading to the heme may be at the origin of the nanosecond component of geminate recombination. Because L-Arg bound in the heme pocket changes the rate of this nanosecond NO-rebinding, it is likely that a structural perturbation occurs that changes the communication between the heme and the channel. Indeed, it was noticed (33) that in a myoglobin mutant with an altered rebinding rate, structural modifications are not seen on x-ray structure. Similar cases likely exist in the NOS isoforms.
L-Arg binding induced a 2-3-order decrease of both kon and koff rates of NO to ferric eNOS measured by stopped flow,2 in agreement with the photodissociation data that reveal a decrease of the overall recombination rate upon L-Arg binding, which accounts for the change of kon. In contrast, L-Arg did not change the kon binding rate of NO for ferric inducible NOSox in the presence of BH4 (25). The magnitude of the effect because of L-Arg on kon and on the geminate recombination rates is not necessarily the same, because geminate rebinding represents only a step of the process determining the on rate. Furthermore, initial conditions differ with stopped flow measurement initiated by mixing NOS and NO solution, whereas photodissociated NO was previously bound to the heme. The overall NO association rate from solution may also include competition with another distal ligand. Photodissociation measurement shows the effect of L-Arg binding free of this competition step, thus closely simulating the situation where NO binds to the heme right after synthesis.
Another effect of L-Arg binding on NO rebinding may be through electrostatic interactions. The proximity of the guanidinium part of L-Arg to the heme-liganded NO is revealed by x-ray structure (38, 39), EPR spectroscopy (24) and also by Raman scattering (23). Without L-Arg, the ferrous NO complex is unstable and is changed from a hexa- to a penta-coordinated species with an unbound proximal Cys (24). Because L-Arg perturbs the electronic state of the ferrous heme-NO complex, as seen by the alteration of EPR spectrum, the electronic barrier for rebinding is likely to change, contributing to the modification of the rate distribution of the picosecond recombination.
In the presence of L-Arg, kon for NO binding did not change for the ferrous eNOS, as measured with stopped flow,2 whereas it changed for ferric eNOS. We observed a slight difference in the rates of the picosecond components, the fastest one being increased for the reduced heme, which thus discloses a modified barrier. No change occurred for the nanosecond component, consistent with the influence of the heme redox state being limited to the heme pocket. During the catalytic activity of nNOS a ferrous-nitrosyl complex formed (20), whereas a ferric one was revealed in the case of inducible NOS (19). Because the proposed reaction mechanisms involve a Fe3+ heme in the last step where NO is formed (15, 16), this difference of redox state of the complex may be due to different rates of NADPH reduction between both isoforms, as suggested earlier (25). In one case, rereduction may occur before NO leaves the heme pocket. This difference in redox state of the nitrosyl complexes is associated with different picosecond rebinding, and the isoform specificity may thus correlate with different requirements for catalytic regulation.
The formation of the ferrous nitrosyl nNOS complex was not decreased by
NO scavengers or by enzyme dilution (20), and it was suggested that two
phases could occur in self-inhibition of NOS by NO, involving a step in
which NO binds to the heme right after synthesis, before leaving the
heme pocket. The properties of geminate rebinding after NO release in
heme pocket are consistent with such a process. Indeed the "gating"
effect of L-Arg on the rebinding modifies the exchange
pathway from the heme to the rest of the molecule and consequently
changes the overall affinity for NO. The effect of L-Arg is
outlined in Fig. 6A. On the
potential energy curve, two energy barriers are modified upon
L-Arg binding. The first one, from the heme pocket to the
heme distal ligand position, decreased, whereas the second one, from
the protein cage to the heme pocket, is raised.
|
Mechanistic Implications-- X-ray structures and simulations have revealed that no direct pathway exists from the heme pocket of myoglobin and hemoglobin to exterior of the protein and that fluctuations of the structure are required for entry into and exit from diatomic ligands (51). For myoglobin the fast rebinding component dominates (Fig. 4) without a significant nanosecond component, we may conclude that in eNOS the pathway from and to the heme pocket is relatively open and less dependent on protein fluctuations than in myoglobin. This is consistent with its physiological function, with substrate L-Arg binding and L-citrulline product release.
From the effects of L-Arg on the NO binding dynamics, we can draw features regarding eNOS activity regulation by NO. A consequence of modulating NO ligation is the possibility of controlling the heme occupancy; this is outlined in Fig. 6B. A direct ligation of L-citrulline to the heme may occur, as indicated by an electronic spectral perturbation and by EPR spectral perturbation (48). This may happen in the last step of L-Arg oxidation. However, the absence of L-Arg results in a heme pocket conformation change that increases the probability of NO rebinding to the heme and L-citrulline release. This would increase turnover efficiency and provide a fast regulation by means of "short term storage."
A striking point is that the two rebinding phases are differently influenced by L-Arg. This leads to a subtle regulation of NO rebinding at different levels (directly in the heme pocket and in the exchange pathway with solution). Because NO is a very reactive species that cannot be stored after synthesis, a regulation of NOS by the formation of nitrosyl complexes should be better achieved through control of NO rebinding without leaving the heme pocket rather than through an equilibrium involving NO already in solution. We are currently undertaking further experiments to clarify these mechanisms.
Conclusion--
The self-inhibition of NOS by ligation of NO newly
synthesized to the heme prior to release from the protein core has been hypothesized (19, 20). We show that geminate recombination of NO does
occur and that this process is modulated by the substrate. When NO is
released in the heme pocket of eNOS, the rebinding to the iron is a
multiphasic process with at least three kinetic components. We assigned
the fastest picosecond phase to geminate rebinding of NO that is still
located in the heme pocket. In contrast to the first one, the slowest
phase, in nanosecond time scale, is influenced by the absence or the
presence of the reductase domain. We thus assigned it to rebinding of
NO located in the protein core but not in the heme pocket. The presence
of only L-Arg on its binding site differently modulates the
rates and the relative amplitudes of both phases of recombination.
L-Arg induces a structural perturbation of the heme pocket
in the ferric state and directly influences the geminate binding of NO
just released in the heme pocket, providing a possible mechanism of subtle and efficient regulation of NO synthesis and release by means of
self-inhibition of eNOS. This may be achieved, once L-Arg is depleted, by a temporary storage of released NO.
| |
ACKNOWLEDGEMENT |
|---|
We thank Dr. S. Franzen for providing the MEM analysis software.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant GM44911 (to A.-L. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed. Tel.: 33-1-69-31-97-97; Fax: 33-1-69-31-99-96; E-mail: negrerie@enstay.ensta.fr.
2 V. Berka and A.-L. Tsai, unpublished results.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: NOS, nitric-oxide synthase; eNOS, endothelial NOS; BH4, tetrahydrobiopterin; SVD, singular value decomposition; MEM, maximum entropy method.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bredt, D. S., and Snyder, S. H. (1994) Annu. Rev. Biochem. 63, 175-195[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Stuehr, D. J. (1997) Annu. Rev. Pharmacol. Toxicol. 37, 339-359[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Tatoyan, A.,
and Giulivi, C.
(1998)
J. Biol. Chem.
273,
11044-11048 |
| 4. | Ignarro, L. J. (1996) Kidney Int. Suppl. 55, S2-S5[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Cooke, J. P., and Dzau, V. J. (1997) Annu. Rev. Med. 48, 489-509[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Marin, J., and Rodriguez-Martinez, M. A. (1997) Pharmacol. Ther. 75, 111-134[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Garbers, D. L.,
and Lowe, D. G.
(1994)
J. Biol. Chem.
269,
30741-30744 |
| 8. |
Stuehr, D. J.,
Kwon, N. S.,
Nathan, C. F.,
Griffith, O. W.,
Feldman, P. L.,
and Wiseman, J.
(1991)
J. Biol. Chem.
266,
6259-6263 |
| 9. |
Hevel, J. M.,
White, K. A.,
and Marletta, M. A.
(1991)
J. Biol. Chem.
266,
22789-22791 |
| 10. |
Marletta, M. A.
(1993)
J. Biol. Chem.
268,
12231-12234 |
| 11. |
Abu-Soud, H. M.,
and Stuehr, D. J.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
10769-10772 |
| 12. |
Matsuoka, A.,
Stuehr, D. J.,
Olson, J. S.,
Clark, P.,
and Ikeda-Saito, M.
(1994)
J. Biol. Chem.
269,
20335-20339 |
| 13. |
Chen, P.-F.,
Tsai, A.-L.,
and Wu, K. K.
(1994)
J. Biol. Chem.
269,
25062-25066 |
| 14. |
Chen, P.-F.,
Tsai, A.-L.,
Berka, V.,
and Wu, K. K.
(1996)
J. Biol. Chem.
271,
14631-14635 |
| 15. |
Klatt, P.,
Schmidt, K.,
Uray, G.,
and Mayer, B.
(1993)
J. Biol. Chem.
268,
14781-14787 |
| 16. | Clague, M. J., Wishnok, J. S., and Marletta, M. A. (1997) Biochemistry 36, 14665-14673 |
| 17. | Zhang, H. Q., Fast, W., Marletta, M. A., Martásek, P., and Silverman, R. B. (1997) J. Med. Chem. 21, 3869-3870 |
| 18. |
Garvey, E. P.,
Oplinger, J. A.,
Furfine, E. S.,
Kiff, R. J.,
Lazlo, F.,
Whittle, B. J.,
and Knowles, R. G.
(1997)
J. Biol. Chem.
272,
4959-4963 |
| 19. | Hurshman, A. R., and Marletta, M. A (1995) Biochemistry 34, 5627-5634[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Abu-Soud, H. M.,
Wang, J.,
Rousseau, D. L.,
Fukuto, J. M.,
Ignarro, L. J.,
and Stuehr, D. J.
(1995)
J. Biol. Chem.
270,
22997-23006 |
| 21. | Rogers, N. E., and Ignarro, L. J. (1992) Biochem. Biophys. Res. Commun. 189, 242-249[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Berka, V.,
Chen, P.-F.,
and Tsai, A.-L.
(1996)
J. Biol. Chem.
271,
33293-33300 |
| 23. |
Wang, J.,
Rousseau, D. L.,
Abu-Soud, H. M.,
and Stuehr, D. J.
(1994)
Proc. Nat. Acad. Sci, U. S. A.
91,
10512-10516 |
| 24. | Migita, C. T., Salerno, J. C., Masters, B. S., Martásek, P., McMillan, K., and Ikeda-Saito, M. (1997) Biochemistry 36, 10987-10992[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Abu-Soud, H. M., Wu, C., Ghosh, D. K., and Stuehr, D. J. (1998) Biochemistry 37, 3777-3786[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Martin, J.-L., and Vos, M. H. (1992) Annu. Rev. Biophys. Biomol. Struct. 21, 199-222[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Press, W. H., Flannery, B. P., Teukolsky, S. A., and Vetterling, W. T. (1988) Numerical Recipes , pp. 51-62, Cambridge University Press, Cambridge |
| 28. | Bretthorst, G. L. (1989) in Maximum Entropy and Bayesian Methods (Skilling, J., ed) , pp. 377-388, Kluwer, Dordrecht, The Netherlands |
| 29. |
Steinbach, P. J.,
Chu, K.,
Fraunfelder, H.,
Johnson, J. B.,
Lamb, D. C.,
Nienhaus, G. U.,
Saub, T. B.,
and Young, R. D.
(1992)
Biophys. J.
61,
235-245 |
| 30. | Presta, A., Liu, J., Sessa, W. C., and Stuehr, D. J. (1997) Nitric Oxide 1, 74-87 [CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Livesey, A. K., Licinio, P., and Delaye, M. (1986) J. Chem. Phys. 84, 5102-5107[CrossRef] |
| 32. | Petrich, J. W., Lambry, J.-C., Kuczera, K., Karplus, M., Poyart, C., and Martin, J.-L. (1991) Biochemistry 30, 3975-3987[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Petrich, J. W., Lambry, J.-C., Balasubramanian, S., Lambright, D G., Boxer, S. G., and Martin, J.-L. (1994) J. Mol. Biol. 238, 437-444[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Gibson, Q. H.,
Regan, R.,
Elber, R.,
Olson, J. S.,
and Carver, T. E.
(1992)
J. Biol. Chem.
267,
22022-22034 |
| 35. | Carlson, M. L, Regan, R. M., and Gibson, Q. H. (1996) Biochemistry 35, 1125-1136[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Elber, R.,
and Karplus, M.
(1987)
Science
235,
318-321 |
| 37. |
Ikeda-Saito, M.,
Dou, Y.,
Yonateni, T.,
Olson, J.,
Li, T.,
Regan, R.,
and Gibson, Q. H.
(1993)
J. Biol. Chem.
268,
6855-6857 |
| 38. |
Crane, B. R.,
Arvai, A. S.,
Ghosh, D. K.,
Wu, C.,
Getzoff, E. D.,
Stuehr, D. J.,
and Tainer, J. A.
(1998)
Science
279,
2121-2126 |
| 39. | Raman, C. S., Li, H., Martásek, P., Král, V., Masters, B. S., and Poulos, T. L. (1998) Cell 95, 939-950[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Rodriguez-Crespo, I., and Ortiz de Montellano, P. R. (1996) Arch. Biochem. Biophys. 336, 151-156[CrossRef][Medline] [Order article via Infotrieve] |
| 41. |
Venema, R. C.,
Ju, H.,
Zou, R.,
Ryan, J. W.,
and Venema, V. J.
(1997)
J. Biol. Chem.
272,
1276-1282 |
| 42. |
Hellermann, G. R.,
and Solomonson, L. P.
(1997)
J. Biol. Chem.
272,
12030-12034 |
| 43. |
Li, H.,
Elber, R.,
and Straub, J. E.
(1993)
J. Biol. Chem.
268,
17908-17916 |
| 44. |
Chen, P.-F.,
Tsai, A.-L.,
Berka, V.,
and Wu, K. K.
(1997)
J. Biol. Chem.
272,
6114-6118 |
| 45. |
Lim, M.,
Jackson, T. A.,
and Anfinrud, P. A.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
5801-5804 |
| 46. |
Kuczera, K.,
Lambry, J.-C.,
Martin, J.-L.,
and Karplus, M.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
5805-5807 |
| 47. |
Tsai, A.-L.,
Berka, V.,
Chen, P.-F.,
and Palmer, G.
(1996)
J. Biol. Chem.
271,
32563-32571 |
| 48. |
Salerno, J. C.,
Frey, C.,
McMillan, K.,
Williams, R. F.,
Masters, B. S.,
and Griffith, O. W.
(1995)
J. Biol. Chem.
270,
27423-27428 |
| 49. | Salerno, J. C., McMillan, K., and Masters, B. S. (1996) Biochemistry 35, 11839-11845[CrossRef][Medline] [Order article via Infotrieve] |
| 50. | McMillan, K., and Masters, B. S. (1993) Biochemistry 32, 9875-9880[CrossRef][Medline] [Order article via Infotrieve] |
| 51. | Perutz, M. F., and Matthews, F. S. (1996) J. Mol. Biol. 21, 199-202 |